138 related articles for article (PubMed ID: 35749080)
1. Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer.
Loret N; Vandamme N; De Coninck J; Taminau J; De Clercq K; Blancke G; Jonckheere S; Goossens S; Lemeire K; De Prijck S; Verstaen K; Seurinck R; Van Dorpe J; Weyers S; Denys H; Van de Vijver K; Lambrecht BN; Tummers P; Saeys Y; Berx G
Mol Cancer Res; 2022 Oct; 20(10):1532-1547. PubMed ID: 35749080
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell‑fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer.
Han Q; Huang B; Huang Z; Cai J; Gong L; Zhang Y; Jiang J; Dong W; Wang Z
Int J Mol Med; 2019 Dec; 44(6):2245-2255. PubMed ID: 31638162
[TBL] [Abstract][Full Text] [Related]
3. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
[TBL] [Abstract][Full Text] [Related]
6. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
7. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M
Gynecol Oncol; 2018 Jan; 148(1):79-85. PubMed ID: 29157627
[TBL] [Abstract][Full Text] [Related]
8. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
10. Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
Xu J; Lu W; Wei X; Zhang B; Yang H; Tu M; Chen X; Wu S; Guo T
Cancer Lett; 2024 Jul; 593():216928. PubMed ID: 38714290
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
[TBL] [Abstract][Full Text] [Related]
12. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
13. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
14. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
Xu AM; Haro M; Walts AE; Hu Y; John J; Karlan BY; Merchant A; Orsulic S
Sci Adv; 2024 Apr; 10(16):eadk8805. PubMed ID: 38630822
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
16. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
18. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
19. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract][Full Text] [Related]
20. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]